- Blog
- GEICAM en SABCS20: estudios RegistEM, PEARL, PANGEA-Breast y TAKEDA
GEICAM en SABCS20: estudios RegistEM, PEARL, PANGEA-Breast y TAKEDA
martes 17 noviembre 2020Participamos en el congreso americano San Antonio Breast Cancer Symposium (SABCS) 2020, que este año se celebra del 8 al 11 de diciembre de forma virtual, con diversos pósteres de los estudios GEICAM/2014-03 (RegistEM), GEICAM/2013-02 (PEARL) y GEICAM/2015-04 (PANGEABreast) y una discusión de póster del estudio GEICAM/2015-07 (TAKEDA).
En concreto, presentamos los siguientes pósteres:
- Characteristics of HR+/HER2- patients with recurrent disease from a prospective registry of unresectable locally advanced or metastatic breast cancer: GEICAM/2014-03 (RegistEM)
- A prospective registry of advanced breast cancer: a subset of triple negative breast cancer patients with her2 low expression: GEICAM/2014-03 (RegistEM)
- Mutational profile from circulating tumor DNA in triple negative breast cancer: results from the prospective registry of unresectable locally advanced or metastatic breast cancer GEICAM/2014-03 (RegistEM)
- Characteristics of HR+/HER2- patients with recurrent disease by HER2 expression from a prospective registry of unresectable locally adavanced or metastasic breast cancer: GEICAM/2014-03 (RegistEM)
- Characteristics of a subset of patients with Triple Negative subtype from a
- prospective registry of unresectable locally advanced or metastatic breast cancer: GEICAM/2014-03 (RegistEM)
- Association of Tumor Infiltrating Lymphocytes (TILs) density and PD-L1 expression with pembrolizumab (P) plus gemcitabine (Gem) efficacy in patients with HER2-negative advanced breast cancer (ABC) from the GEICAM/2015-04 (PANGEABreast)study
- PLK1 expression and efficacy of palbociclib in advanced hormonal receptorpositive breast cancer patients from PEARL study (GEICAM/2013-02)
Y la discusión de póster “Open-label, randomized, phase 2 study of sapanisertib (TAK-228/MLN0128) incombination with fulvestrant in postmenopausal women with estrogen receptor-positive (ER+)/human epidermal growth factor receptor-2-negative (HER2-) advanced or metastatic breast cancer (MBC) that previously progressed during or after aromatase inhibitor therapy (NCT02756364)
Más información